Shelton Capital Management’s Abiomed Inc ABMD Stock Holding History

Shelton Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,697	Closed	-$785K	–	891
2018 Q1	$785K	Hold	2,697	–	–	0.05%	266
2017 Q4	$505K	Hold	2,697	–	–	0.03%	377
2017 Q3	$455K	Hold	2,697	–	–	0.03%	396
2017 Q2	$386K	Hold	2,697	–	–	0.03%	445
2017 Q1	$338K	Sell	2,697 -3,273	-55%	-$379K	0.02%	517
2016 Q4	$673K	Hold	5,970	–	–	0.05%	297
2016 Q3	$768K	Buy	5,970 +2,697	+82%	+$323K	0.06%	256
2016 Q2	$358K	Hold	3,273	–	–	0.03%	483
2016 Q1	$310K	Buy	3,273 +446	+16%	+$37.6K	0.03%	551
2015 Q4	$255K	Hold	2,827	–	–	0.02%	615
2015 Q3	$262K	Buy	+2,827	New	+$249K	0.03%	591
2015 Q2	–	Sell	-2,827	Closed	-$202K	–	811
2015 Q1	$202K	Buy	+2,827	New	+$153K	0.02%	766

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shelton Capital Management's ABMD Position: Q2 2018 in Review

Shelton Capital Management sold out of Abiomed Inc (ABMD) in Q2 2018, closing a stake of 2,697 shares — an estimated $785K sold.

Shelton Capital Management first reported a position in ABMD in Q1 2015 and held it in 12 quarters. The position peaked at $785K in Q1 2018. 527 funds tracked by Wall St. Rank hold ABMD as of Q2 2018.

Shelton Capital Management reported no remaining Abiomed Inc position as of Q2 2018 after selling out during the quarter.
Shelton Capital Management sold 2,697 Abiomed Inc shares in Q2 2018, an estimated $785K.
Shelton Capital Management first reported a position in Abiomed Inc in Q1 2015 and held it in 12 quarters.
Shelton Capital Management's Abiomed Inc position peaked at $785K in Q1 2018.
527 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2018.

Based on Shelton Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.